Log In
Print
BCIQ
Print
Print this Print this
 

Anthim (ETI-204)

  Manage Alerts
Collapse Summary General Information
Company Elusys Therapeutics Inc.
DescriptionAffinity enhanced mAb against Bacillus anthracis protective antigen to inhibit binding of anthrax toxins
Molecular Target Bacillus anthracis protective antigen
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase I/II
IndicationAnthrax
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today